Clinical trial
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
NCT06876649 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- May 20, 2025
- Completion date
- December 31, 2032
- Enrollment
- 787 (estimated)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia, non-hodgkin lymphoma